Erasca, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $769.00K, a 90.35% increase year-over-year.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $404.00K, a 2.28% increase year-over-year.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $395.00K, a 25.05% decline year-over-year.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $527.00K, a 14.59% decline year-over-year.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $724.00K, a 9.50% decline from fiscal 2024.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $800.00K, a 1.27% increase from fiscal 2023.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $790.00K, a 3.66% decline from fiscal 2022.
- Erasca, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $820.00K, a 23.15% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $769.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $724.00K 10-K · filed 2026-03-12 | |
| 2025-06-30 | $404.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $800.00K 10-K · filed 2026-03-12 | |
| 2024-06-30 | $395.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $790.00K 10-K · filed 2025-03-20 | |
| 2023-06-30 | $527.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $820.00K 10-K · filed 2024-03-27 | |
| 2022-06-30 | $617.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $1.07M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |